TP53 and ovarian serous adenocarcinoma: Furthermore, when combined with other therapies, WEE1 inhibition can lead to synergistic anti-tumor effects in several cancer types with limited treatment alternatives, such as recurrent uterine serous cancer with TP53 mutation (Liu et al. 2021), high-grade serous ovarian cancer with platinum resistance (Leijen et al. 2016b; Lheureux et al. 2021), and unresectable pancreatic cancer (Cuneo et al. 2019).